144 related articles for article (PubMed ID: 30275193)
1. Identification of Two Types of Stem Cells in Methylene Blue-stained Sections of Untreated and Diethylstilbestrol-treated Human Prostate Cancer and Their Characterization by Immunogold Localization of CD133.
Sinha AA; Wilson MJ
Anticancer Res; 2018 Oct; 38(10):5725-5732. PubMed ID: 30275193
[TBL] [Abstract][Full Text] [Related]
2. Electron Microscopic Analysis of Stem Cells in Human Prostate Cancer, Including Inverted Capsule Embedding Methods for Archival Sections and Falcon Films for Prostate Cancer Cell Lines.
Sinha AA
Anticancer Res; 2019 Aug; 39(8):4171-4177. PubMed ID: 31366502
[TBL] [Abstract][Full Text] [Related]
3. Concurrent Androgen and Estrogen Ablation and Inhibition of Steroid Biosynthetic Enzyme Treatment for Castration-resistant Prostate Cancer.
Sinha AA; Pomroy FE; Wilson MJ
Anticancer Res; 2016 Aug; 36(8):3847-54. PubMed ID: 27466486
[TBL] [Abstract][Full Text] [Related]
4. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens.
Miki J; Furusato B; Li H; Gu Y; Takahashi H; Egawa S; Sesterhenn IA; McLeod DG; Srivastava S; Rhim JS
Cancer Res; 2007 Apr; 67(7):3153-61. PubMed ID: 17409422
[TBL] [Abstract][Full Text] [Related]
5. Human epithelial basal cells are cells of origin of prostate cancer, independent of CD133 status.
Taylor RA; Toivanen R; Frydenberg M; Pedersen J; Harewood L; ; Collins AT; Maitland NJ; Risbridger GP
Stem Cells; 2012 Jun; 30(6):1087-96. PubMed ID: 22593016
[TBL] [Abstract][Full Text] [Related]
6. Expression analysis of putative stem cell markers in human benign and malignant prostate.
Ugolkov AV; Eisengart LJ; Luan C; Yang XJ
Prostate; 2011 Jan; 71(1):18-25. PubMed ID: 20583131
[TBL] [Abstract][Full Text] [Related]
7. Role of canine basal cells in prostatic post natal development, induction of hyperplasia, sex hormone-stimulated growth; and the ductal origin of carcinoma.
Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
Prostate; 2001 May; 47(3):149-63. PubMed ID: 11351344
[TBL] [Abstract][Full Text] [Related]
8. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma.
Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
Prostate; 2001 Aug; 48(3):210-24. PubMed ID: 11494337
[TBL] [Abstract][Full Text] [Related]
9. The identification of a novel antibody for CD133 using human antibody phage display.
Glumac PM; Forster CL; Zhou H; Murugan P; Gupta S; LeBeau AM
Prostate; 2018 Sep; 78(13):981-991. PubMed ID: 29790189
[TBL] [Abstract][Full Text] [Related]
10. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model.
Bonkhoff H; Remberger K
Prostate; 1996 Feb; 28(2):98-106. PubMed ID: 8604398
[TBL] [Abstract][Full Text] [Related]
11. Isolation, characterization and mobilization of prostate cancer tissue derived CD133+ MDR1+ cells.
Rentala S; Mangamoori LN
J Stem Cells; 2010; 5(2):75-81. PubMed ID: 22049617
[TBL] [Abstract][Full Text] [Related]
12. CD133 does not enrich for the stem cell activity in vivo in adult mouse prostates.
Wei X; Orjalo AV; Xin L
Stem Cell Res; 2016 May; 16(3):597-606. PubMed ID: 27010655
[TBL] [Abstract][Full Text] [Related]
13. Co-Expression of Putative Cancer Stem Cell Markers CD44 and CD133 in Prostate Carcinomas.
Kalantari E; Asgari M; Nikpanah S; Salarieh N; Asadi Lari MH; Madjd Z
Pathol Oncol Res; 2017 Oct; 23(4):793-802. PubMed ID: 28083789
[TBL] [Abstract][Full Text] [Related]
14. Prominin-1 (CD133) is not restricted to stem cells located in the basal compartment of murine and human prostate.
Missol-Kolka E; Karbanová J; Janich P; Haase M; Fargeas CA; Huttner WB; Corbeil D
Prostate; 2011 Feb; 71(3):254-67. PubMed ID: 20717901
[TBL] [Abstract][Full Text] [Related]
15. Prospective identification of tumorigenic prostate cancer stem cells.
Collins AT; Berry PA; Hyde C; Stower MJ; Maitland NJ
Cancer Res; 2005 Dec; 65(23):10946-51. PubMed ID: 16322242
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells.
Huss WJ; Gray DR; Greenberg NM; Mohler JL; Smith GJ
Cancer Res; 2005 Aug; 65(15):6640-50. PubMed ID: 16061644
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Midkine Suppresses Prostate Cancer CD133
Erdogan S; Doganlar ZB; Doganlar O; Turkekul K; Serttas R
Am J Med Sci; 2017 Sep; 354(3):299-309. PubMed ID: 28918838
[TBL] [Abstract][Full Text] [Related]
18. Characterization of CD133
Güler G; Guven U; Oktem G
Analyst; 2019 Mar; 144(6):2138-2149. PubMed ID: 30742170
[TBL] [Abstract][Full Text] [Related]
19. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
[TBL] [Abstract][Full Text] [Related]
20. Enrichment of putative prostate cancer stem cells after androgen deprivation: upregulation of pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell lines.
Seiler D; Zheng J; Liu G; Wang S; Yamashiro J; Reiter RE; Huang J; Zeng G
Prostate; 2013 Sep; 73(13):1378-90. PubMed ID: 23728788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
